Relugolix reduces leiomyoma extracellular matrix production via the transforming growth factor-beta pathway
Relugolix regulated leiomyoma size by decreasing COL1A1, FN1, and VCAN production. This effect is at least partly through the TGF-β pathway.
Authors
- Paul H. Driggers
- Adina Schwartz
- William H. Catherino (ORCID: https://orcid.org/0000-0002-8783-6999)
- Minnie Malik (ORCID: https://orcid.org/0000-0003-1129-6575)
Institutions
- Uniformed Services University of the Health Sciences (US)
Publication Details
- Journal
- F&S Science
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1016/j.xfss.2024.12.004
- Citations
- 1
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.58
Funders
- Uniformed Services University of the Health Sciences